Roadshow
AI DeepExoMir
GGA Corp. independently developed the DeepExoMir platform, leveraging AI deep learning and multimodal feature engineering to focus on regenerative medicine, skin repair, hair regeneration, and immune modulation.
GGA Corp. independently developed the DeepExoMir platform, leveraging AI deep learning and multimodal feature engineering to focus on regenerative medicine, skin repair, hair regeneration, and immune modulation. The platform analyzes miRNA functions and integrates a biological pathway database to enable key pathway regulation and automated indication recommendations. Using the Exo-W index, it quantifies functional differences across product sources. DeepExoMir offers advantages in cross-species, multi-source, and end-to-end biological pathway interpretation, achieving prediction accuracy above 0.96. Since its launch in 2023, it has supported multiple product validations and market entries. Over the next three years, DeepExoMir will advance cloud-based SaaS and API integration, expand international partnerships, and drive scalable, high-value applications in the exosome industry.
- Established 2008
- Company GGA Corp.
- Telephone +886-2795-1777#2686
- Email BryceLin@GGA.ASIA
- Address No. 28, Ln. 36, Xinhu 1st Rd., Neihu Dist., Taipei City 114065, Taiwan (R.O.C.)
GGA Corp. is strategically focused on three core business domains: Genetic Medicine, Digital AI Technology, and Precision Health. Within the Digital AI Technology sector, GGA’s portfolio encompasses laboratory data management, scientific simulation, and extends to cutting-edge applications including exosome-based regenerative medicine, AI-driven process optimization, 5G materials, electric vehicle batteries, energy efficiency and carbon reduction technologies, semiconductor materials, and medical big data analytics. The company leverages advanced intelligent R&D capabilities to pioneer innovative cross-sector business opportunities.
GGA’s comprehensive suite of products and services—covering cellular therapies, exosome platforms, genetic testing, diagnostics, and medical aesthetics—currently supports over 50% of newborns in Taiwan, 95% of reproductive medicine centers, and more than 500 healthcare institutions nationwide. The company’s footprint extends to 17 international markets, having served over 1.85 million individuals to date.